Brigatinib
Sign in to save this workspacePrimary targets: ALK · FDA status: FDA Approved
Selectivity scorecard
KISS
82.96
Gini
0.513
CATDS
0.006
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Brigatinib. Strongest target: CAMK2D at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CAMK2D | 100.0% | 0.0% |
| 2 | ERBB2_HER2 | 100.0% | 0.0% |
| 3 | CAMK2A | 99.7% | 0.3% |
| 4 | CHK2 | 99.4% | 0.6% |
| 5 | CLK1 | 99.4% | 0.6% |
| 6 | STK22D_TSSK1 | 99.3% | 0.7% |
| 7 | ALK | 99.2% | 0.8% |
| 8 | PYK2 | 99.1% | 0.9% |
| 9 | RSK3 | 98.5% | 1.5% |
| 10 | EGFR | 98.5% | 1.5% |
| 11 | SIK2 | 98.4% | 1.6% |
| 12 | FER | 98.2% | 1.8% |
| 13 | ROS_ROS1 | 98.2% | 1.8% |
| 14 | FLT3 | 98.1% | 1.9% |
| 15 | AMPK(A1_B2_G2) | 98.0% | 2.0% |
| 16 | ACK1 | 98.0% | 2.0% |
| 17 | AMPK(A2_B1_G2) | 97.9% | 2.1% |
| 18 | BRK | 97.8% | 2.2% |
| 19 | MYO3B | 97.6% | 2.4% |
| 20 | ERBB4_HER4 | 97.6% | 2.4% |
Selectivity landscape
Where Brigatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Brigatinib.
Annotations
Sign in to read and post annotations.
Loading…